ACB
Price
$5.73
Change
-$0.23 (-3.86%)
Updated
Oct 1, 04:59 PM (EDT)
Capitalization
335.35M
36 days until earnings call
YCBD
Price
$1.17
Change
-$0.05 (-4.13%)
Updated
Oct 1, 04:59 PM (EDT)
Capitalization
10.16M
Interact to see
Advertisement

ACB vs YCBD

Header iconACB vs YCBD Comparison
Open Charts ACB vs YCBDBanner chart's image
Aurora Cannabis
Price$5.73
Change-$0.23 (-3.86%)
Volume$24.31K
Capitalization335.35M
CBDMD
Price$1.17
Change-$0.05 (-4.13%)
Volume$797
Capitalization10.16M
ACB vs YCBD Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YCBD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. YCBD commentary
Oct 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and YCBD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 02, 2025
Stock price -- (ACB: $5.96 vs. YCBD: $1.21)
Brand notoriety: ACB: Notable vs. YCBD: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 218% vs. YCBD: 142%
Market capitalization -- ACB: $335.35M vs. YCBD: $10.16M
ACB [@Pharmaceuticals: Generic] is valued at $335.35M. YCBD’s [@Pharmaceuticals: Generic] market capitalization is $10.16M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.13B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileYCBD’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • YCBD’s FA Score: 1 green, 4 red.
According to our system of comparison, YCBD is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 7 TA indicator(s) are bullish while YCBD’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 7 bullish, 3 bearish.
  • YCBD’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ACB is a better buy in the short-term than YCBD.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а +18.49% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was +82.89% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.59%. For the same industry, the average monthly price growth was +38.73%, and the average quarterly price growth was +90.63%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.59% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($335M) has a higher market cap than YCBD($10.2M). ACB has higher P/E ratio than YCBD: ACB (19.44) vs YCBD (2.24). ACB YTD gains are higher at: 40.235 vs. YCBD (-59.667). ACB has higher annual earnings (EBITDA): 26.6M vs. YCBD (163K). ACB has more cash in the bank: 140M vs. YCBD (1.06M). YCBD has less debt than ACB: YCBD (963K) vs ACB (102M). ACB has higher revenues than YCBD: ACB (358M) vs YCBD (19M).
ACBYCBDACB / YCBD
Capitalization335M10.2M3,284%
EBITDA26.6M163K16,319%
Gain YTD40.235-59.667-67%
P/E Ratio19.442.24870%
Revenue358M19M1,884%
Total Cash140M1.06M13,208%
Total Debt102M963K10,592%
FUNDAMENTALS RATINGS
ACB vs YCBD: Fundamental Ratings
ACB
YCBD
OUTLOOK RATING
1..100
7536
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9399
PRICE GROWTH RATING
1..100
4139
P/E GROWTH RATING
1..100
901
SEASONALITY SCORE
1..100
8516

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YCBD's Valuation (51) in the Other Consumer Services industry is in the same range as ACB (58) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to ACB’s over the last 12 months.

YCBD's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as YCBD (99) in the Other Consumer Services industry. This means that ACB’s stock grew similarly to YCBD’s over the last 12 months.

YCBD's Price Growth Rating (39) in the Other Consumer Services industry is in the same range as ACB (41) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to ACB’s over the last 12 months.

YCBD's P/E Growth Rating (1) in the Other Consumer Services industry is significantly better than the same rating for ACB (90) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew significantly faster than ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBYCBD
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 16 days ago
79%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YCBD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BFRI0.990.02
+1.77%
Biofrontera
HURA2.480.01
+0.40%
TuHURA Biosciences Inc
HAFN5.99N/A
N/A
Hafnia Limited
TECK43.89-0.21
-0.48%
Teck Resources Limited
MPB28.64-0.33
-1.14%
Mid Penn Bancorp

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with SNDL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-4.33%
SNDL - ACB
65%
Loosely correlated
-2.19%
CGC - ACB
64%
Loosely correlated
-7.01%
OGI - ACB
62%
Loosely correlated
+3.05%
CRON - ACB
58%
Loosely correlated
-6.40%
TLRY - ACB
54%
Loosely correlated
-6.49%
More

YCBD and

Correlation & Price change

A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with TLRY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then TLRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YCBD
1D Price
Change %
YCBD100%
-12.32%
TLRY - YCBD
38%
Loosely correlated
-6.49%
ACB - YCBD
34%
Loosely correlated
-4.33%
RDHL - YCBD
29%
Poorly correlated
-7.26%
OGI - YCBD
29%
Poorly correlated
+3.05%
RGEDF - YCBD
28%
Poorly correlated
N/A
More